Pharmacists Adopted New Lipid Therapy Guidelines
Clinical pharmacists are integrating into cardiovascular-kidney-metabolic care teams under new national guidelines.
Updated on Sept. 28, 2026 in Heart Disease
Live Poll
Do you trust pharmacists to make independent adjustments to your chronic medication prescriptions?
At the 2026 NEIAP Annual Forum, Kelsey Norman of Boston Medical Center introduced new cardiovascular-kidney-metabolic (CKM) syndrome guidelines. The framework establishes clinical pharmacists as essential interdisciplinary team members in lipid management.
Why it matters
The shift addresses clinical inertia and persistent failure to meet LDL-C goals by leveraging the expanded time and expertise pharmacists offer patients. This model aims to improve medication adherence and therapy intensification through direct consultation.
New clinical guidelines now prioritize triple lipid-lowering regimens, while the phase 3 Lp(a)HORIZON trial for pelacarsen recently failed to reach its primary end point. The long-term efficacy of new injectable agents remains under investigation.
The players
Kelsey Norman
A clinician affiliated with Boston Medical Center who presented updated cardiovascular guidelines.
NEIAP
The professional organization that hosted the 2026 Annual Forum in Boston where new cardiovascular standards were presented.
Yale New Haven Health
The healthcare system that served as the clinical site for the PROMPT-Lipid trial studying electronic health record alerts.
The details
Pharmacists utilize collaborative practice agreements to adjust medications independently, while electronic health record alerts, as seen in the Yale New Haven Health PROMPT-Lipid trial, have proven to increase therapy intensification. FDA labeling has also expanded to allow evolocumab for primary prevention in high-risk patients, and combining ezetimibe with bempedoic acid is now available at the same cost as the latter alone.
Timeline
The CKM syndrome guidelines were released during the 2026 NEIAP Annual Forum in Boston.
The Big Picture
This integration follows a pattern of digital and interdisciplinary care intensification previously established by the PROMPT-Lipid trial. The new guidelines mark a shift toward pharmacist-led lipid management protocols in standard practice.
Patients may now receive more frequent and direct medication consultations from pharmacists who are authorized to adjust lipid-lowering therapies independently. These team-based adjustments are designed to help more individuals reach their cholesterol targets through consistent, guideline-driven care.
The takeaway
Patients should discuss the potential for pharmacist-led medication management with their primary care providers to ensure therapy remains current. Staying proactive about lipid-lowering regimens can help bridge gaps when standard treatments fail to reach target cholesterol levels.
Further reading
Learn more about evolving treatment standards in our Heart Disease section.
Source note: This article includes information reported by Pharmacytimes.
Live Poll
Do you trust pharmacists to make independent adjustments to your chronic medication prescriptions?
